Multicenter prospective observational study of dupilumab‐induced ocular events in atopic dermatitis patients
2 PhAN - Physiopathologie des Adaptations Nutritionnelles
3 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
4 DMG Nantes - Département de médecine générale [Nantes Université - UFR de Médecine et des Techniques Médicales]
5 CHU Reims - Hôpital universitaire Robert Debré [Reims]
6 CardioVir - Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320
7 Université de Clermont-Ferrand
8 Service Ophtalmologie [CHU Clermont-Ferrand]
9 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
10 UCL - Université catholique de Lille
11 Service de Dermatologie [Nice]
12 CHU Nice - Centre Hospitalier Universitaire de Nice
13 Service de Dermatologie [Rouen]
14 Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen]
15 ESCAPE - Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle
16 Service d'ophtalmologie [Rouen]
17 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires
18 CIRI-EIA - Immunité de l’épiderme & allergie - Epidermal Immunity and Allergy [CIRI]
19 Service Dermatologie [CHU Toulouse]
20 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
21 CIRI - Centre International de Recherche en Infectiologie
22 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
23 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
24 INFINITE - Institute for Translational Research in Inflammation - U 1286
25 CHU Tenon [AP-HP]
26 CIRID - Composantes innées de la réponse immunitaire et différenciation
- Fonction : Auteur
- PersonId : 1295930
- ORCID : 0000-0003-1057-1010
- Fonction : Auteur
- PersonId : 1228214
- IdHAL : aurelie-gaultier
- ORCID : 0000-0002-8266-1210
- IdRef : 271453850
- Fonction : Auteur
- PersonId : 1295931
- ORCID : 0000-0002-7696-3511
- Fonction : Auteur
- PersonId : 1529297
- ORCID : 0000-0001-9066-7092
- IdRef : 068631669
- Fonction : Auteur
- PersonId : 756820
- ORCID : 0000-0001-6245-7442
- IdRef : 197536719
- Fonction : Auteur
- PersonId : 793025
- ORCID : 0000-0003-2281-9052
- IdRef : 122796853
- Fonction : Auteur
- PersonId : 786587
- ORCID : 0000-0001-5286-9689
- Fonction : Auteur
- PersonId : 1226028
- ORCID : 0000-0001-8930-1042
- Fonction : Auteur
- PersonId : 775956
- ORCID : 0000-0002-8726-6658
- IdRef : 131367218
- Fonction : Auteur
- PersonId : 775154
- ORCID : 0000-0003-1139-0908
- IdRef : 129977373
- Fonction : Auteur correspondant
- PersonId : 1202886
- ORCID : 0000-0002-6629-9100
- IdRef : 130885282
Connectez-vous pour contacter l'auteur
Résumé
Abstract Background Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination. Objective To examine the incidence, characteristics and risk factors of dupilumab‐induced ocular adverse events. Methods A prospective, multicenter, and real‐life study in adult AD patients treated with dupilumab. Results At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab‐induced blepharoconjunctivitis: either de novo ( n = 32) or worsening of underlying blepharoconjunctivitis ( n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938–30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635–21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158–13.90]; p = 0.031) were independent factors associated with dupilumab‐induced blepharoconjunctivitis. Limitations Our follow‐up period was 16 weeks and some late‐onset time effects may still occur. Conclusion This study showed that most dupilumab‐induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.